Statement of Comprehensive Income

Comprehensive income is the change in equity (net assets) of a business enterprise during a period from transactions and other events and circumstances from non-owners sources. It includes all changes in equity during a period except those resulting from investments by owners and distributions to owners.

Pfizer Inc., consolidated statement of comprehensive income

US$ in millions

12 months ended:	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Net income before allocation to noncontrolling interests	2,158)	31,407)	22,025)	9,652)	16,302)
Foreign currency translation adjustments, net	485)	(2,204)	(725)	1,036)	400)
Reclassification adjustments	—)	—)	—)	(17)	(288)
Foreign currency translation adjustments	485)	(2,204)	(725)	1,019)	112)
Unrealized holding gains (losses) on derivative financial instruments, net	514)	1,261)	442)	(494)	393)
Reclassification adjustments for (gains) losses included in net income	(320)	(1,792)	105)	46)	(539)
Derivative financial instruments	194)	(531)	547)	(448)	(146)
Unrealized holding gains (losses) on available-for-sale securities, net	(106)	(1,142)	(311)	316)	(1)
Reclassification adjustments for (gains) losses included in net income	(123)	1,583)	(26)	(164)	34)
Available-for-sale securities	(229)	441)	(337)	152)	33)
Actuarial gains (losses), net	—)	—)	—)	(847)	(657)
Reclassification adjustments related to amortization	—)	—)	—)	214)	186)
Reclassification adjustments related to settlements, net	—)	—)	—)	213)	209)
Other	—)	—)	—)	(183)	31)
Actuarial gains (losses)	—)	—)	—)	(603)	(231)
Prior service (costs) credits and other, net	(20)	(19)	89)	40)	(6)
Reclassification adjustments related to amortization of prior service costs and other, net	(89)	(100)	(107)	(145)	(138)
Reclassification adjustments related to curtailments of prior service costs and other, net	(11)	(9)	(57)	—)	(1)
Other	—)	—)	—)	(1)	1)
Prior service (costs) credits and other	(120)	(128)	(75)	(106)	(144)
Benefit plans	(120)	(128)	(75)	(709)	(375)
Other comprehensive income (loss) before allocation to noncontrolling interests	330)	(2,422)	(590)	14)	(376)
Comprehensive income before allocation to noncontrolling interests	2,488)	28,985)	21,435)	9,666)	15,926)
Comprehensive income attributable to noncontrolling interests	(26)	(20)	(42)	(27)	(18)
Comprehensive income attributable to Pfizer Inc.	2,462)	28,965)	21,393)	9,639)	15,908)

Based on: 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31).

Download chart

Comprehensive income item	Description	The company
Net income attributable to Pfizer Inc.	The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.	Pfizer Inc. net income attributable to Pfizer Inc. increased from 2021 to 2022 but then decreased significantly from 2022 to 2023.
Comprehensive income attributable to Pfizer Inc.	Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Exclude changes in equity resulting from investments by owners and distributions to owners.	Pfizer Inc. comprehensive income attributable to Pfizer Inc. increased from 2021 to 2022 but then decreased significantly from 2022 to 2023.

Pfizer Inc. (NYSE:PFE)

Statement of Comprehensive Income